Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies

The high cost of gene therapies has proved a sticking point for the personalized medicines in recent years, most notably prompting bluebird bio to withdraw its blood disorder treatment Zynteglo in Europe after running into an ‘untenable’ pricing situation with the bloc.